Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu The US approval sparks a $125m payment to Daiichi Sankyo from AZ – the first milestone payment in the alliance. ... Sales of Enhertu in the US will be booked by Daiichi Sankyo with AZ claiming a share of gross profits.

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla Among the rivals is Daiichi Sankyo and AstraZeneca’s  trastuzumab deruxtecan (DS-8201), another ADC currently under regulatory review for patients with advanced HER2-positive breast cancer that have failed Kadcyla

AZ, Daiichi Sankyo strengthen case for HER2 candidate

AZ, Daiichi Sankyo strengthen case for HER2 candidate Will rival Roche's HER2 franchise if approved. AstraZeneca’s big bet on a Daiichi Sankyo-developed HER2-targeting antibody-drug conjugate looks like its about to pay off, after delivering ... AZ and Daiichi Sankyo are looking at a possible approval for

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo US-based biotech is arguing the legal action is improper. Seattle Genetics has asked a court to dismiss a lawsuit brought a few weeks ago by Japan’s Daiichi Sankyo centring ... The two companies previously collaborated on ADC drug development between

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201 Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”. ... The original agreement between the companies cover ADCs

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics